The company discontinued development last month of its most mature asset, RLYB212, following disappointing mid-stage ...

The system is so named as it is known to “complement ... One example cited is eculizumab, which inhibits the C5 complement protein and is well known for its use to treat several complement ...

Cambridge, Massachusetts-based Vor Bio has confirmed that it will halt clinical and manufacturing operations, including its ...

Learn more about whether ACADIA Pharmaceuticals Inc. or BioCryst Pharmaceuticals, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Learn more about whether BioCryst Pharmaceuticals, Inc. or PTC Therapeutics, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

In April 2025, Novartis Pharmaceuticals announced study is to establish the efficacy, safety, and tolerability of ...

Additional information regarding these results and other relevant information is included in the notes to the financial statements in “Item 18. Financial Statements”, which are included in InflaRx’s ...

Announces successful completion of sub-chronic and chronic toxicology studies for INF904, supporting long-term dosing in future clinical trialsMultiple near-term catalysts anticipated with the potenti ...

Citroën has announced the second generation of its C5 Aircross SUV, which will be available in hybrid, plug-in hybrid, and ...

Google's Android operating system can be attacked in versions 13, 14 and 15 due to vulnerabilities. Among other things, attackers can gain higher user rights as a result. In the worst case ...

Enjoy 4K TV shows and movies in all their cinematic glory with a brilliant 65-inch TV When you purchase through links on our site, we may earn an affiliate commission. Here’s how it works. In my ...

April 29, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics ...